The development of therapeutics targeting MondoA and ChREBP is an active area of research, given their important roles in regulating glucose and lipid metabolism and their potential as targets for the treatment of diabetes, obesity, and metabolic diseases. The gene discussed is MLXIPL; the disease is obesity due to melanocortin 4 receptor deficiency.